Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Investment
Ionis and Roche sign antisense pact
by Ryan Cross
October 13, 2018
| A version of this story appeared in
Volume 96, Issue 41
Roche is teaming up with the antisense oligonucleotide company Ionis Pharmaceuticals to advance a treatment for dry age-related macular degeneration. Ionis has already completed a Phase I study and will begin a Phase II study in early 2019 with a fresh $75 million in up-front payments from Roche. If Roche likes the results, it may acquire the experimental treatment, and Ionis could earn up to $684 million in milestone payments.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X